{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:22:20Z","timestamp":1794864140914,"version":"4.9.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008484","name":"biomarin pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients are the most important stakeholders in the care of any disease and have an educational need to learn about their condition and the treatment they should receive. Considering this need for patient-focused materials, we present a directed approach for mucopolysaccharidosis (MPS) VI and MPS IVA, a pair of rare, inherited diseases that affects multiple organs and parts of the body. Independent guidelines on the treatment of these diseases were recently published, providing evidence- and expertise-driven recommendations to optimize patient management. However, while healthcare providers may have the training and knowledge to understand these guidelines, patients and their caregivers can find the technical content challenging. Hence, we aimed to develop plain language summaries (PLS) of the MPS VI and MPS IVA guidelines with patients as the primary audience.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A review of the guidelines by an expert team identified six domains of information relevant to patients: The multidisciplinary team, regular tests and check-ups, disease-modifying and supportive treatments, general anesthetics, ear-nose-throat\/respiratory care, and surgeries. This information was adapted into a series of infographics specific to either MPS VI or MPS IVA, designed to appeal to patients and clearly present information in a concise manner.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The use of patient-friendly materials, like the infographics we have developed, has the potential to better inform patients and engage them in their care. We issue a \u201ccall to arms\u201d to the medical community for the development of similar PLS materials in rare diseases intended to inform and empower patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-022-02219-7","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T06:03:14Z","timestamp":1646200994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Addressing the need for patient-friendly medical communications: adaptation of the 2019 recommendations for the management of MPS VI and MPS IVA"],"prefix":"10.1186","volume":"17","author":[{"given":"Iain A.","family":"Bruce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih S.","family":"Ezg\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kampmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Kenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2179-3639","authenticated-orcid":false,"given":"Christian","family":"Hendriksz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"issue":"Suppl 5","key":"2219_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/rheumatology\/ker394","volume":"50","author":"J Muenzer","year":"2011","unstructured":"Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50(Suppl 5):4\u201312.","journal-title":"Rheumatology (Oxford)"},{"key":"2219_CR2","doi-asserted-by":"crossref","unstructured":"Coutinho MF, Lacerda L, Alves S. Glycosaminoglycan storage disorders: a review. Biochem Res Int. 2012;2012:471325.","DOI":"10.1155\/2012\/471325"},{"issue":"1","key":"2219_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10545-013-9613-3","volume":"37","author":"LD Archer","year":"2014","unstructured":"Archer LD, Langford-Smith KJ, Bigger BW, Fildes JE. Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity. J Inherit Metab Dis. 2014;37(1):1\u201312.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"2219_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00381-014-2578-1","volume":"31","author":"A Leone","year":"2015","unstructured":"Leone A, Rigante D, Amato DZ, Casale R, Pedone L, Magarelli N, Colosimo C. Spinal involvement in mucopolysaccharidoses: a review. Childs Nerv Syst. 2015;31(2):203\u201312.","journal-title":"Childs Nerv Syst"},{"issue":"1","key":"2219_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11926-013-0389-0","volume":"16","author":"R Cimaz","year":"2014","unstructured":"Cimaz R, La Torre F. Mucopolysaccharidoses. Curr Rheumatol Rep. 2014;16(1):389.","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"2219_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1750-1172-5-5","volume":"5","author":"V Valayannopoulos","year":"2010","unstructured":"Valayannopoulos V, Nicely H, Harmatz P, Turbeville S. Mucopolysaccharidosis VI. Orphanet J Rare Dis. 2010;5(1):5.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2219_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13023-019-1080-y","volume":"14","author":"MU Akyol","year":"2019","unstructured":"Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, et al. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis. 2019;14(1):118.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2219_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2174\/138920111795542615","volume":"12","author":"S Tomatsu","year":"2011","unstructured":"Tomatsu S, Monta\u00f1o AM, Oikawa H, Smith M, Barrera L, Chinen Y, et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr Pharm Biotechnol. 2011;12(6):931\u201345.","journal-title":"Curr Pharm Biotechnol"},{"issue":"1","key":"2219_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13023-019-1074-9","volume":"14","author":"MU Akyol","year":"2019","unstructured":"Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, et al. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis. 2019;14(1):137.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2219_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ymgme.2013.01.021","volume":"109","author":"P Harmatz","year":"2013","unstructured":"Harmatz P, Mengel KE, Giugliani R, Valayannopoulos V, Lin SP, Parini R, et al. The Morquio A clinical assessment program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab. 2013;109(1):54\u201361.","journal-title":"Mol Genet Metab"},{"issue":"Suppl 3","key":"2219_CR11","doi-asserted-by":"publisher","first-page":"S788","DOI":"10.1007\/s11606-014-2895-9","volume":"29","author":"LP Forsythe","year":"2014","unstructured":"Forsythe LP, Szydlowski V, Murad MH, Ip S, Wang Z, Elraiyah TA, et al. A systematic review of approaches for engaging patients for research on rare diseases. J Gen Intern Med. 2014;29(Suppl 3):S788-800.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"2219_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13023-018-0969-1","volume":"14","author":"K Young","year":"2019","unstructured":"Young K, Kaminstein D, Olivos A, Burroughs C, Castillo-Lee C, Kullman J, et al. Patient involvement in medical research: what patients and physicians learn from each other. Orphanet J Rare Dis. 2019;14(1):21.","journal-title":"Orphanet J Rare Dis"},{"key":"2219_CR13","first-page":"2","volume":"2","author":"S Litzkendorf","year":"2016","unstructured":"Litzkendorf S, Babac A, Rosenfeldt D, Schauer F, Hartz T, L\u00fchrs V, et al. Information needs of people with rare diseases - what information do patients and their relatives require? Rare Disord Diagn Ther. 2016;2:2.","journal-title":"Rare Disord Diagn Ther"},{"key":"2219_CR14","doi-asserted-by":"crossref","unstructured":"Uhlenbusch N, L\u00f6we B, Depping MK. Perceived burden in dealing with different rare diseases: a qualitative focus group study. BMJ Open. 2019;9(12):e033353.","DOI":"10.1136\/bmjopen-2019-033353"},{"key":"2219_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1087\/20140303","volume":"27","author":"E Nunn","year":"2014","unstructured":"Nunn E, Pinfield S. Lay summaries of open access journal articles: engaging with the general public on medical research. Learn Publ. 2014;27:173\u201384.","journal-title":"Learn Publ"},{"issue":"4","key":"2219_CR16","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1177\/2168479017738723","volume":"52","author":"DS Pushparajah","year":"2018","unstructured":"Pushparajah DS, Manning E, Michels E, Arnaudeau-B\u00e9gard C. Value of developing plain language summaries of scientific and clinical articles: a survey of patients and physicians. Ther Innov Regul Sci. 2018;52(4):474\u201381.","journal-title":"Ther Innov Regul Sci"},{"issue":"3","key":"2219_CR17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.mayocp.2017.01.001","volume":"92","author":"MH Murad","year":"2017","unstructured":"Murad MH. Clinical Practice Guidelines: A primer on development and dissemination. Mayo Clin Proc. 2017;92(3):423\u201333.","journal-title":"Mayo Clin Proc"},{"key":"2219_CR18","doi-asserted-by":"crossref","unstructured":"Pavan S, Rommel K, Mateo Marquina ME, H\u00f6hn S, Lanneau V, Rath A. Clinical practice guidelines for rare diseases: the Orphanet Database. PLoS One. 2017;12(1):e0170365.","DOI":"10.1371\/journal.pone.0170365"},{"key":"2219_CR19","unstructured":"Muir E. The Rare Reality \u2013 an insight into the patient and family experience of rare disease. Rare Disease UK. 2016. Available at: https:\/\/www.raredisease.org.uk\/media\/1588\/the-rare-reality-an-insight-into-the-patient-and-family-experience-of-rare-disease.pdf. Last accessed June 2021."},{"issue":"20","key":"2219_CR20","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.4103\/0366-6999.243569","volume":"131","author":"M Balkac","year":"2018","unstructured":"Balkac M, Ergun E. Role of infographics in healthcare. Chin Med J (Engl). 2018;131(20):2514\u20137.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"2219_CR21","first-page":"48","volume":"5","author":"LJ Martin","year":"2019","unstructured":"Martin LJ, Turnquist A, Groot B, Huang SYM, Kok E, Thoma B, et al. Exploring the role of infographics for summarizing medical literature. Health Prof Edu. 2019;5(1):48\u201357.","journal-title":"Health Prof Edu"},{"key":"2219_CR22","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez Silvagnoli L, Shepherd C, Pritchett J, Gardner J. How can we optimize the readability and format of plain language summaries for medical journal articles? A cross-sectional survey study. J Med Internet Res. 29\/09\/2021;22122 (forthcoming\/in press).","DOI":"10.2196\/22122"},{"issue":"6","key":"2219_CR23","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/mgg3.315","volume":"5","author":"C von der Lippe","year":"2017","unstructured":"von der Lippe C, Diesen PS, Feragen KB. Living with a rare disorder: a systematic review of the qualitative literature. Mol Genet Genomic Med. 2017;5(6):758\u201373.","journal-title":"Mol Genet Genomic Med"},{"key":"2219_CR24","doi-asserted-by":"crossref","unstructured":"Boycott KM, Lau LP, Cutillo CM, Austin CP. International collaborative actions and transparency to understand, diagnose, and develop therapies for rare diseases. EMBO Mol Med. 2019;11(5):e10486.","DOI":"10.15252\/emmm.201910486"},{"key":"2219_CR25","unstructured":"European Medicines Agency. Naglazyme (galsulfase). Summary of product characteristics. 2020. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/naglazyme-epar-product-information_en.pdf. Last accessed June 2021."},{"key":"2219_CR26","unstructured":"US Food and Drug Administration. Naglazyme (galsulfase). US prescribing information. 2019. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125117s129lbl.pdf. Last accessed June 2021."},{"key":"2219_CR27","unstructured":"European Medicines Agency. Vimizim (elosulfase alfa). Summary of product characteristics. 2018. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vimizim-epar-product-information_en.pdf. Last accessed June 2021."},{"key":"2219_CR28","unstructured":"US Food and Drug Administration. Vimizim (elosulfase alfa). US prescribing information. 2019. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125460s017lbl.pdf. Last accessed June 2021."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02219-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02219-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02219-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T06:11:58Z","timestamp":1646201518000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02219-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2219"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02219-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-801127\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,2]]},"assertion":[{"value":"10 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publications"}},{"value":"FSE has received consultancy and speaker fees from BioMarin, Takeda, and Sanofi Genzyme paid to their institution, travel grants from Pfizer and Sanofi Genzyme, and has participated as an investigator for clinical trials sponsored by Sobi and Sanofi Genzyme. WM has received speaker fees from BioMarin and Web MD Medscape paid to their institutional honorarium, received a Biobank research grant from BioMarin paid to their institution, and has acted as a non-paid consultant to Little People of America and the MPS Society on medical advisory boards. BS has received grants paid to the MPS Society from Takeda, BioMarin, and Regenxbio for speaker fees and payments. CH was employed by and owned shares in FYMCA Medical Ltd. until October 2020.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}